Journal of Clinical Oncology
Articles in this Issue
New pediatric formulation of asciminib in children with chronic myeloid leukemia in chronic phase: Second interim analysis of pharmacokinetics and safety from the ASC4Kids study.
10027 Background: More treatment (tx) options to improve efficacy and long-term safety to minimize adverse effects on growth are needed for pediatric pati...
Effects of socioeconomic status on access to next generation sequencing in patients with metastatic breast cancer.
1610 Background: Metastatic breast cancer is difficult to treat and a major cause of mortality related to breast cancer. Standard treatment includes thera...
Costs of ovarian cancer care since the introduction of poly (ADP-ribose) polymerase inhibitors (PARPis).
e17568 Background: The objective of this study was to evaluate changes in medical and pharmacy costs among ovarian cancer (OC) patients since poly (ADP-ri...
Stereotactic body radiotherapy combined with PD-1 antibody in unresectable colorectal liver metastases: A prospective, multicenter, single-arm, phase II study (SPARKLE-L).
TPS3639 Background: Colorectal cancer liver metastasis (CRLM) significantly decreases colorectal cancer (CRC) patient prognosis, affecting 30-50% of CRC p...
Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung trial explores metastasis-associated alterations and potential prognostic markers.
8537 Background: Lung adenocarcinoma (LUAD) molecular heterogeneity influences diagnosis, prognosis, and treatment. Molecular profiling of advanced lesion...
The impact of IDH mutation and 1p/19q codeletion on immune-checkpoint inhibitor efficacy in recurrent gliomas.
2053 Background: Recurrent gliomas are highly aggressive brain tumors, often resistant to conventional treatments. Immune checkpoint inhibitors (ICI) have...
A novel cellular immunotherapy using vaccine generated neoantigen-specific effector T cells.
2537 Background: Cellular immunotherapy languished in obscurity until genetically engineered chimeric antigen receptor T cells were shown to effectively t...
Achieving global breast cancer initiative key performance indices for breast cancer patients in Botswana by HIV status.
1628 Background: Low- to middle-income countries have disproportionately higher breast cancer (BC) mortality rates, partly due to late-stage diagnosis. In...
Treatment rechallenge after trastuzumab-deruxtecan–related interstitial lung disease: A multi-institution cohort study.
1015 Background: T-DXd is an antibody-drug conjugate approved for advanced HER2+/low/ultra-low breast cancer and multiple...
Evaluating RECIST criteria in resource-limited settings: Guatemala experience.
e23115 Background: RECIST criteria were published in 2000 and updated in 2009 to RECIST 1.1, being the gold standard for tumor evaluation in clinical tria...
Patterns of mortality in lung cancer patients in the era of immunotherapy and targeted therapy: A single-center, retrospective, observational study.
e20627 Background: Over the past decade, immunotherapies and targeted therapies have revolutionized the treatment of lung cancer patients. While the outco...
Treatment (Tx) patterns and decision drivers in Chinese patients (pts) with locally advanced cervical cancer (LACC): Results from a national physician survey.
e17501 Background: Cervical cancer (CC) is the fourth most common and lethal cancer in women, with ~23% in Chinese pts. We sought to characterize real-wor...
Trends and disparities in lung cancer– and cardiovascular disease–related mortality among older adults in the United States: A CDC-WONDER analysis.
e22535 Background: Lung Cancer remains the leading cause of cancer-related death both in the U.S. and worldwide. Current evidence suggests that lung cance...
Irinotecan, temozolomide and naxitamab plus GM-CSF (HITS) and naxitamab plus GM-CSF and ifosfamide, carboplatin, etoposide (NICE) for patients with relapsed or refractory high-risk neuroblastoma: A single center, open-label phase 2 clinical trial.
10039 Background: Patients with relapsed/refractory (R/R) high-risk neuroblastoma (HR-NB) have a poor prognosis, underscoring the need to explore new ther...
Role of pelareorep in activating anti-tumor immunity in PDAC.
2562 Background: Pancreatic ductal adenocarcinoma (PDAC) is highly lethal cancer with limited immunotherapeutic options. Pelareorep (pela) is an intraveno...
Comparison of sequential intravesical gemcitabine and docetaxel versus bacillus Calmette-Guérin in the treatment of non-muscle invasive bladder cancer: A meta-analysis.
e16603 Background: Bacillus Calmette-Guérin (BCG) is considered the standard treatment for non-muscle invasive bladder cancer (NMIBC). However, the global...
Utilization of tumor-informed ctDNA to de-escalate treatment or monitoring in metastatic breast cancer exceptional responders.
e13042 Background: The conventional treatment paradigm for metastatic breast cancer (MBC) is to continue systemic therapy until disease progression. With...
Immune biomarkers as predictors of response to mosunetuzumab in previously untreated follicular (FL) and marginal zone lymphoma (MZL).
7063 Background: CD3xCD20 bispecific antibodies (BsAbs), including mosunetuzumab, induce high rates of complete response (CR) in indolent B-cell lymphomas...
Effect of broad-based genomic sequencing on survival outcomes in advanced non-small cell lung cancer: A national cohort study, 2011-2023.
1520 Background: Use of broad-based genomic sequencing (BGS) for advanced non-small cell lung cancer (aNSCLC) is rising. While older studies have found no...
Clinical predictors and prognostic significance of pathologic disease upstaging at radical cystectomy (RC) in patients with muscle-invasive bladder cancer (MIBC).
e16601 Background: Imaging and cystoscopy can frequently underestimate disease stage in MIBC. We evaluated clinical and pathological predictors of patholo...
TRENT-002: A prospective, multicenter, randomized controlled phase II study to evaluate the efficacy and safety of salvage preoperative PD-1 inhibitor combined with chemotherapy neoadjuvant therapy in recurrent laryngeal/hypopharyngeal squamous cell carcinoma (L/HPSCC).
TPS6119 Background: Salvage surgery is considered the standard of care for patients with resectable recurrent L/HPSCC. However, salvage surgery achieves d...
Potential impact of non-exonuclease <i>POLE</i> and <i>POLD1</i> mutations on high and ultrahigh TMB across cancers.
e14558 Background: DNA polymerases ε ( POLE ) and δ1 ( POLD1 ) encode enzymes involved in DNA replication...
The HealthTree Cure Hub registry: A patient-centered, multicenter approach to advancing multiple myeloma care.
e19569 Background: Multiple myeloma (MM) is the second most common hematologic malignancy, with an increasing incidence worldwide. Clinical registries pro...
AI-driven reflectance confocal microscopy for noninvasive diagnosis and accurate surgical margin assessment intra-operatively in oral cavity squamous cell carcinoma.
6082 Background: Oral cavity squamous cell carcinoma (SCC) remains a common malignancy in the head and neck region, with challenges in tumor resection and...
Use of plasma metabolomic profile to predict breast cancer survival: Risk stratification based on tumor nutrient dependencies.
e12545 Background: Breast cancer is the most common cancer in women. Metabolic reprogramming is a hallmark of the disease. The propensity of cancer cells...